Viewing nowCombinationRinaglometh Extended Release Tablet 5/1000 mg (Rinaglipti, Metformin)
Linagliptin Micronized 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.

MFDS item code 202400188 · Approved 2024.01.24 · Insurance code 643508760
Improves blood glucose control in type 2 diabetes
This medication is used to help control blood sugar levels in patients with type 2 diabetes who are taking rinaglipti and metformin together. It aids in effectively managing blood sugar levels alongside dietary and exercise therapy, contributing to stable blood glucose levels and diabetes treatment.
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole without splitting, crushing, grinding, or chewing. This drug may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredient. If a patient repeatedly reports finding this drug in the stool, the healthcare provider should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients treated with metformin - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug similar to the patient's current dose of metformin hydrochloride, together with a total daily dose of linagliptin 5mg, should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with Caution in the Following Patients). - When switching from immediate-release metformin to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be equivalent to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before starting this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A) whose creatinine clearance (CrCl) is ≥ 45mL/min and < 60mL/min or whose estimated glomerular filtration rate (eGFR) is ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this drug may be used with metformin hydrochloride dose adjustment as described below, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to < 45mL/min or estimated glomerular filtration rate (eGFR) decreases to < 45mL/min/1.73m2, this drug should be discontinued immediately.
This medication can, rarely, cause a serious condition known as lactic acidosis; therefore, it should not be used in patients with renal impairment, acute infections, dehydration, or severe trauma. Patients who are allergic to any active ingredients of this medication, patients with type 1 diabetes, and those with severe hepatic impairment should also not receive this treatment. Caution should be exercised when used in combination with insulin or sulfonylureas due to the risk of hypoglycemia, and the dosage of those medications may need to be reduced if necessary. Renal function should be regularly monitored, especially in the elderly or those with declining renal function. Skin conditions such as acute pancreatitis or bullous pemphigoid may occur; thus, immediate consultation with a doctor is advised if severe abdominal pain or skin abnormalities arise during treatment. This medication should be swallowed whole, without breaking, crushing, grinding, or chewing, and the shell of the tablet may appear in the stool, which is normal. Additionally, vitamin B12 levels may decrease, so it's advisable to regularly check vitamin B12 status with long-term use. This medication may interact with other drugs, particularly those that affect renal function or blood glucose levels, so caution is required. It is recommended not to use this medication during pregnancy or while breastfeeding, and women planning for pregnancy should consult a physician. The safety and effectiveness of this medication in children have not been established, so its use in this population is not recommended. In case of overdose, there is a risk of lactic acidosis; thus, immediate medical treatment should be sought. Store this medication out of reach of children and avoid humidity.
Severe lactic acidosis, hypoglycemia, nasopharyngitis, hypersensitivity reactions, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test results, hypoglycemia, taste disorders, cough, loss of appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcers, abnormal liver function tests, hepatitis, pruritus, erythema, rash, pemphigus-like lesions, joint pain accompanied by severity and disability, rhabdomyolysis, increased lipase, increased amylase, constipation, epigastric pain, small intestinal colitis, intestinal obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's type dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pleural effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, cholelithiasis, dizziness, kidney transplant failure, anxiety, affective disorders, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, chest discomfort, myasthenia, pain, epistaxis, oropharyngeal pain, voice disorders, allergic rhinitis, exertional dyspnea, wet cough, rhinorrhea, pulmonary mass, joint pain, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased serum triglycerides, increased urine albumin/creatinine ratio, positive urine leukocytes, reduced hemoglobin, increased serum potassium, increased serum creatinine, increased serum creatine kinase activity, increased ALT, male pattern baldness, hyperhidrosis, hair loss, dermatitis, goiter, confused state, nocturia, dermatitis, hypertension, erectile dysfunction, vitreous hemorrhage, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and humidity, so it should be stored in a closed container. Additionally, it should be kept at room temperature between 1°C and 30°C, avoiding extreme heat or cold.
White oval extended-release film-coated tablet
Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin Micronized 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.